-
Product Insights
Proto Oncogene Tyrosine Protein Kinase Src – Drugs In Development, 2023
Global Markets Direct’s Proto Oncogene Tyrosine Protein Kinase Src provides in depth analysis on Proto Oncogene Tyrosine Protein Kinase Src targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BBP-398 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BBP-398 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BBP-398 in Colorectal Cancer Drug Details: BBP-398 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BBP-398 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BBP-398 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BBP-398 in Pancreatic Ductal Adenocarcinoma Drug Details: BBP-398 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Saracatinib Difumarate in Psychosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saracatinib Difumarate in Psychosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saracatinib Difumarate in Psychosis Drug Details: Saracatinib difumarate (AZD-0530) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Elzovantinib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elzovantinib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elzovantinib in Non-Small Cell Lung Cancer Drug Details: Elzovantinib (TPX-0022)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BBP-398 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BBP-398 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BBP-398 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: BBP-398 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Elzovantinib in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elzovantinib in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elzovantinib in Colorectal Cancer Drug Details: Elzovantinib (TPX-0022) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Elzovantinib in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elzovantinib in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elzovantinib in Gastric Cancer Drug Details: Elzovantinib (TPX-0022) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Elzovantinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elzovantinib in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elzovantinib in Solid Tumor Drug Details: Elzovantinib (TPX-0022) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Elzovantinib in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elzovantinib in Metastatic Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elzovantinib in Metastatic Brain Tumor Drug Details: Elzovantinib (TPX-0022) is under...